The Day – TBBCF 10th Birthday
The Day – TBBCF 10th Birthday Read More »
March 2016
March 2016 TBBCF Newsletter
TBBCF Celebrates Women’s History Month Sharing stories of wonderful women via TBBCF social media Women ‘ s History Month is a celebration of women ‘ s contributions to worldwide culture and society. The United States has observed it annually throughout the month of March since 1987. We have asked various women involved with TBBCF – Board of Directors members,
March 2016 TBBCF Newsletter Read More »
TBBCF Visits DFCI Researcher
TBBCF Visits 2016 Grant Recipient, Daniel Stover, MD, at Dana-Farber Cancer Institute Members of the Terri Brodeur Breast Cancer Foundation visited Dana-Farber Cancer Institute to meet Daniel Stover, MD, one of our 2016 grant recipients. Pictured from left to right, are Daniel Stover, MD; John LaMattina, PhD, Co-Chair of the TBBCF Scientific Advisory Committee, Sandy
TBBCF Visits DFCI Researcher Read More »
TBBCF Visits MGH Researcher
TBBCF Visits 2016 Grant Recipient, Mihriban Karaayvaz, PhD, at Massachusetts General Hospital Cancer Center Another visit on March 17 by members of the Terri Brodeur Breast Cancer Foundation to Massachusetts General Hospital to meet Mihriban Karaayvaz, PhD, one of our 2016 grant recipients. Pictured from left to right are John LaMattina, PhD, Co-Chair TBBCF Scientific
TBBCF Visits MGH Researcher Read More »
The Day Editorial on TBBCF
Brodeur Foundation marks 10 years of bringing good from tragedy. Published March 15, 2016 6:57PM. The Day The success of the Terri Brodeur Breast Cancer Foundation is proof that out of great tragedy can come great good. Breast cancer killed Terri Brodeur in 2005, her 41st year, leaving behind three children and a husband. Before
The Day Editorial on TBBCF Read More »
Update 2015 Promotion Results
More 2015 Fundraising Results At TBBCF, we are in awe of the generous giving by so many individuals, teams, and companies over the years. It was no different in 2015. As you can see in these pictures, it is easy to smile when we think about how these efforts make a difference in the fight
Update 2015 Promotion Results Read More »
Eneda Toska, PhD
Eneda Toska, PhD Memorial Sloan Kettering Cancer Center Mutations in the PIK3CA gene are the most frequent genomic alterations in estrogen receptor (ER)-positive breast cancers. One treatment strategy is the use of drugs that inhibit the gene’s signaling pathway—however, many patients eventually become resistant to this type of therapy. Further, PI3K signaling pathway inhibition has
Daniel G. Stover, MD
Daniel G. Stover, MD Dana-Farber Cancer Institute The host immune system is critical in the control and elimination of tumors in many cancer types. In breast cancer, tumor infiltrating immune cells have been associated with both response to chemotherapy and overall outcome for patients. Understanding what immune cell populations infiltrate tumors may help guide which
Daniel G. Stover, MD Read More »
Mihriban Karaayvaz, PhD
Mihriban Karaayvaz, PhD Mass General Hospital Cancer Center Making a major impact on the incidence and lethality of breast cancer will require a detailed understanding of the early events in breast cancer development, particularly in women who are at the highest risk of developing these cancers such as those who carry mutations in the BRCA1/2
Mihriban Karaayvaz, PhD Read More »
Jean Albrengues, Ph.D.
Jean Albrengues, Ph.D. Ph.D. Cold Spring Harbor Laboratories Dr. Jean Albrengues’ 2016 Terri Brodeur Breast Cancer Foundation fellowship award focuses on the regulation of breast cancer dormancy by the tumor microenvironment. Metastatic breast cancer relapse occurring years after seemingly successful treatment is preceded by an interlude, termed dormancy when cancer remains non-proliferative and undetected at
Jean Albrengues, Ph.D. Read More »